Landos Biopharma: FDA Meeting Clears Path for Omilancor Phase 3 Program

By Michael Dabaie

Landos Biopharma Inc. said it had a successful outcome of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate for mild-to-moderate active ulcerative colitis.

Landos said it and the FDA agreed on key elements necessary for regulatory approval, clearing a path for a Phase 3 program with omilancor.

The program will include two Phase 3 clinical trials and evaluate a single dose of omilancor, with primary objectives of clinical remission at weeks 12 and 52, the company said.

Landos said it is working to finalize the details of the Phase 3 protocols based on feedback and guidance from the FDA.

Ulcerative colitis is a chronic, autoimmune, inflammatory bowel disease that is estimated to affect more than 900,000 patients in the U.S. and over 1 million patients throughout the rest of the world, Landos said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 14, 2021 07:43 ET (11:43 GMT)

Landos Biopharma (NASDAQ:LABP)
Historical Stock Chart
From Aug 2024 to Sep 2024